NEW YORK – ERS Genomics said on Wednesday that it has signed a licensing agreement granting Japanese biotech company FASMAC access to ERS's CRISPR-Cas9 patent portfolio, and the right to use the technology to commercialize tools and reagents associated with it.
Financial details of the transaction were not disclosed.